Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation

Transplant Infectious Disease

Volumn 16, Issue 3, 2014, Pages 379-386

  Steinebrunner, N ^a   Sandig, C ^a   Sommerer, C ^a   Hinz, U ^a   Giese, T ^b   Stremmel, W ^a   Zahn, A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CMV infection; Liver transplantation; NFAT; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GRAFT RECIPIENT; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; RESIDUAL GENE EXPRESSION; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; RISK FACTORS; TACROLIMUS; YOUNG ADULT;

EID: 84901984888     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12206     Document Type: Article

References (22)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342 (9): 605-612.
2. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80 (2 Suppl): S254-S264.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78 (4): 557-565.
4. Fernandez-Marmiesse A, Hermida J, Tutor JC. Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients. Clin Biochem 2000; 33 (5): 383-386.
5. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24 (4): 479-486.
6. Barnard JB, Thekkudan J, Richardson S, et al. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant 2006; 25 (5): 564-568.
7. Marin JG, Levine M, Ensom MH. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006; 28 (5): 637-642.
8. Cambaceres CG, Rojas L, Fernandez MC, et al. Monitoring cyclosporine microemulsion at two hours post dosing in pediatric maintenance liver transplant recipients. Transplant Proc 2010; 42 (1): 361-362.
9. Furlan V, Lykavieris P, Maubert MA, Habes D, Debray D. Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation. Transplant Proc 2009; 41 (8): 3333-3334.
10. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357 (6380): 695-697.
11. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77 (3): 339-344.
12. Zahn A, Schott N, Hinz U, et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transplant 2011; 17 (4): 466-473.
13. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine A in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82 (10): 1280-1285.
14. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transplant Int 2007; 20 (12): 1036-1043.
15. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004; 19 (Suppl 4): iv 55-60.
16. Sommerer C, Hartschuh W, Enk A, Meuer S, Zeier M, Giese T. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008; 22 (5): 549-554.
17. Sommerer C, Zeier M, Czock D, Schnitzler P, Meuer S, Giese T. Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011; 33 (4): 373-379.
18. Ouyang Q, Wagner WM, Wikby A, Remarque E, Pawelec G. Compromised interferon gamma (IFN-gamma) production in the elderly to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype? Eur Cytokine Network 2002; 13 (4): 392-394.
19. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101 (7): 2686-2692.
20. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 2010; 49 (4): 207-221.
21. van den Berg AP, Twilhaar WN, van Son WJ, et al. Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis. Transplant Int 1998; 11 (Suppl 1): S318-S321.
22. Billing H, Giese T, Sommerer C, et al. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplant 2010; 14 (7): 844-851.